Satyendra Dhar, MD @DharSaty · 2 years ago
x.com
Chronic Kidney Disease (CKD): Individualize BP-lowering therapy and treatment targets in people with frailty, high risk of
x.com 
Chronic Kidney Disease (CKD):

Individualize BP-lowering therapy and treatment targets in people with frailty, high risk of falls, very limited life expectancy, or symptomatic postural hypotension.

Treatments that delay progression of CKD with a strong evidence base include RASiand SGLT2i. In people with CKD and heart failure, SGLT2i confer benefits irrespective of albuminuria.

Initial dips in eGFR are expected following initiation of hemodynamically active therapies, including both RASI and SGLT2i. GFR reductions of ≥30% from baseline exceed the expected variability and warrant evaluation.

CKD is not a contraindication to an invasive strategy for people with acute or unstable heart disease. Imaging studies are not necessarily contraindicated in people with CKD and the risks and benefits should be determined on an individual basis.

#CKD #eGFR #Kidney
Satyendra Dhar, MD @DharSaty · 2 years ago
Hospital Medicine Clinical Assistant Professor The content and images on this website are provided for educational and informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. The views expressed are those of the authors and do not necessarily reflect those of any affiliated institutions. While efforts are made to ensure accuracy and currency, medical knowledge is continually evolving, and errors or omissions may occur. Users are advised to independently verify information and seek guidance from qualified healthcare professionals for any medical decisions. By using this website, you acknowledge responsibility for your own clinical judgments, and the website and its contributors disclaim any liability arising from the use of its content. 👉 Follow 'Medical Infographics' on 👉 https://www.DharSaty.com
Related images